Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Quest, Luminex, Danaher, and More

NEW YORK (GenomeWeb) – Quest Diagnostics announced this week that its board of directors has declared a quarterly cash dividend of $.45 per share, payable on April 19 to shareholders of record on April 5.

Luminex said this week that its board of directors has authorized the initiation of a quarterly cash dividend to its shareholders for the first time in the company's history. The dividend of $.06 per share will be payable on April 14 to shareholders of record as of the close of business on March 24. This represents a planned annual dividend of $.24 per share. 

Danaher announced this week that its board of directors has approved a regular quarterly dividend of $.14 per share payable on April 28 to shareholders of record on March 31.

In a filing with the US Securities and Exchange Commission this week, Vermillion said it completed a previously announced private placement. The company sold approximately 3.7 million shares of its common stock at $1.40 per share. Investors also received warrants to purchase up to 2.8 million shares at an exercise price of $1.80 per share. At the closing of the placement, Vermillion received $5.6 million in gross proceeds, and has the potential to raise another $5.1 million if all of the warrants are exercised. The company said it intends to use the net proceeds for general corporate and working capital purposes.

DNA Electronics announced this week that it has opened a new US facility in preparation for commercializing its first product. The new site in Carlsbad, California expands the firm's operations in the US and will serve as a specialized development and manufacturing base for its first product under the LiDia brand, a diagnostic platform.

Privately held life sciences company Blackfynn said this week that it has expanded its relationship with Children's Hospital of Philadelphia. Under the terms of the expanded deal, CHOP and the Children's Brain Tumor Tissue Consortium will use Blackfynn's data platform to analyze non-identifiable patient data in a bid to accelerate the discovery of treatments for childhood brain cancer. The patient data includes pathology, imaging, genomics, EEG, clinical, and other information.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.